Cat. No.: HY-13231

CDK9-IN-1

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

For research use only. We do not sell to patients.

Purity: 98.52%
CAS No.: 1415559-43-1
Formula: C₂₆H₂₁N₅O₄S
Molecular Weight:499.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CDK9-IN-1 Chemical Structure

CAS No.: 1415559-43-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

IC₅₀ & Target^[1]

CDK9/CycT1

39 nM (IC₅₀)

HIV-1

All CDK Isoforms :

All HIV Isoforms :

In Vitro

CDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1415559-43-1
Appearance Solid
Molecular Weight 499.54
Formula C₂₆H₂₁N₅O₄S
Color White to off-white
SMILES

CC1=C(NS(C)(=O)=O)C=C(NC2=NC=NC(C3=CC=CC(N4C(C5=C(C=CC=C5)C4=O)=O)=C3)=C2)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Mol Immunol

Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis. [Abstract]

2021 Jul:135:351-364. PMID: 33990004

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (200.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0018 mL

10.0092 mL

20.0184 mL

5 mM

0.4004 mL

2.0018 mL

4.0037 mL

10 mM

0.2002 mL

1.0009 mL

2.0018 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem. 2011;18(3):342-358. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0018 mL	10.0092 mL	20.0184 mL	50.0460 mL
	5 mM	0.4004 mL	2.0018 mL	4.0037 mL	10.0092 mL
	10 mM	0.2002 mL	1.0009 mL	2.0018 mL	5.0046 mL
	15 mM	0.1335 mL	0.6673 mL	1.3346 mL	3.3364 mL
	20 mM	0.1001 mL	0.5005 mL	1.0009 mL	2.5023 mL
	25 mM	0.0801 mL	0.4004 mL	0.8007 mL	2.0018 mL
	30 mM	0.0667 mL	0.3336 mL	0.6673 mL	1.6682 mL
	40 mM	0.0500 mL	0.2502 mL	0.5005 mL	1.2512 mL
	50 mM	0.0400 mL	0.2002 mL	0.4004 mL	1.0009 mL
	60 mM	0.0334 mL	0.1668 mL	0.3336 mL	0.8341 mL
	80 mM	0.0250 mL	0.1251 mL	0.2502 mL	0.6256 mL
	100 mM	0.0200 mL	0.1001 mL	0.2002 mL	0.5005 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CDK9-IN-1

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Antiviral Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) CDK9-IN-1

All CDK Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CDK9-IN-1

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Antiviral Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) CDK9-IN-1

All CDK Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CDK9-IN-1 Related Classifications

HY-13231 Related Classifications